| Title |
Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2015
|
| DOI | 10.2147/dddt.s84850 |
| Pubmed ID | |
| Authors |
Christopher E Kandel, Sharon L Walmsley |
| Abstract |
Dolutegravir is the newest integrase strand transfer inhibitor to be approved for the treatment of human immunodeficiency virus (HIV) infection. Dolutegravir is equivalent or superior to existing treatment regimens in both treatment-naïve and treatment-experienced patients including those with previous raltegravir or elvitegravir failure. The consistent efficacy coupled with excellent tolerability and infrequent drug-drug interactions makes the co-formulation of dolutegravir with two nucleotide reverse-transcriptase inhibitors an attractive treatment option. This review summarizes the pharmacokinetics, adverse event profile, and efficacy of dolutegravir in the treatment of HIV. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 30% |
| Venezuela, Bolivarian Republic of | 2 | 20% |
| Netherlands | 1 | 10% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 70% |
| Practitioners (doctors, other healthcare professionals) | 3 | 30% |
Mendeley readers
The data shown below were compiled from readership statistics for 260 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | <1% |
| Argentina | 1 | <1% |
| Unknown | 257 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 36 | 14% |
| Student > Bachelor | 36 | 14% |
| Researcher | 26 | 10% |
| Student > Ph. D. Student | 26 | 10% |
| Student > Postgraduate | 24 | 9% |
| Other | 40 | 15% |
| Unknown | 72 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 78 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 41 | 16% |
| Biochemistry, Genetics and Molecular Biology | 11 | 4% |
| Immunology and Microbiology | 10 | 4% |
| Chemistry | 10 | 4% |
| Other | 23 | 9% |
| Unknown | 87 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2024.
All research outputs
#1,774,781
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#77
of 2,254 outputs
Outputs of similar age
#21,573
of 277,879 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 155 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,879 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.